Introduction: Vitamin D deficiency is common worldwide with adverse effects on skeletal health. In recent years, there has been great interest in non-classical actions of vitamin D. Basic research has uncovered actions in a range of non-skeletal tissues, and observational studies have identified inverse relationships with risk of a number of disease states including sarcopenia, obesity, the metabolic syndrome, cardiovascular disease, cancer and autoimmune diseases.
Introduction
One billion people globally have been estimated to have vitamin D deficiency. 1 Severe deficiency results in the clinical syndromes of rickets and osteomalacia, which remain a problem in low-income countries but are rare (although increasing) in the 'developed-world'. Fortification of foods with vitamin D is used in parts of Europe and North America and over-the-counter supplementation is widespread. Risk factors for vitamin D deficiency include lack of sunlight exposure (including latitude >30°in winter time), skin pigmentation, low dietary intake (meat, fish, eggs, fortified foods), medications (including anti-convulsants, anti-retrovirals and glucocorticoids), extremes of age, obesity as well as associations with chronic disease states. 2 Deficiency is also highly prevalent even in regions with year round sun exposure including South America, the Middle East and Asia. 3 A recent analysis of available data in Europe estimated that 13% of the population had 25-hydroxyvitamin D (25OHD) levels <30 nmol/l, this equates to 14.1 million individuals in the UK, rising to 32.6 million if the higher threshold of <50 nmol/l is used. 4 There is concern that this represents a growing public health problem, characterized as pandemic in some quarters. 4, 5 Worldwide populations are changing,
with an ageing population in high-income countries, global migration patterns, and an increase in obesity and non-communicable diseases in low-to middle-income countries. 6 These changes will impact on the prevalence and management of vitamin D deficiency in years to come. Laboratory testing to determine serum 25OHD concentrations is increasing, and concerns have been raised on resulting health economic burden. The cost per test is in the region of £35 currently, however, with the increased frequency of testing of a large at risk population, the overall liability could be considerable. 7 Vitamin D has established roles in bone health and mineral metabolism, and supplementation is advocated in guidelines in cases of deficiency to prevent falls and fractures. 2, [8] [9] [10] In recent years with the identification of vitamin D receptors (VDRs) in various tissues, and with observational studies reporting associations between serum vitamin D status and a range of disease outcomes, there has been increased interest in the extra-skeletal effects. In this review, we outline our current knowledge of the effect of deficiency in the developed world, in a range of diseases. Calcitriol is cleared by 24-hydroxylation into inactive metabolites by the enzyme 24-hydroxylase in the kidney with the end-products largely excreted in bile. 13 Local tissue activation of unbound 25OHD to calcitriol is thought to drive 'non-classical' actions.
Vitamin D physiology

Sources of data
Data were collected from literature searches of online databases including PUBMED, MEDLINE and Cochrane. A narrative/non-systematic review was performed.
Areas of agreement
The role of vitamin D in bone and mineral metabolism is well established. All current guidelines support the use of serum 25OHD to assess vitamin D status due to its long half-life (21-30 days, compared to 4-15 h for calcitriol) and stable serum levels, and reflection of total body stores. 8, 9 There was broad agreement on the use of vitamin D with calcium supplementation to improve skeletal outcomes. [8] [9] [10] higher thresholds for deficiency (50 nmol/l) and insufficiency (52.5-72.5 nmol/l). These thresholds are based on data looking at PTH cut-offs, intestinal calcium absorption, which are consistent with data on fracture rates although it is possible that for extra-skeletal indications disease-specific targets would be preferable.
Dosing strategies
NOS stated that oral vitamin D 3 was the treatment of choice, whereas the Endocrine Society did not express a preference. In addition, there is a lack of evidence to demonstrate superiority of a lower daily or a higher dose intermittent strategy. The Endocrine Society and NOS agreed on the use of an induction dose of vitamin D (such as 300 000 IU total divided over 6-10 weeks) in adults followed by maintenance dosing. 8, 9 It was noted, however, that most studies were focused on short-term as opposed to long-term outcomes. Annual dosing of vitamin D was discounted, in view of data suggesting lack of efficacy and increased fracture risk. One randomized study observed an increased rate of falls in those treated with annual oral dose of 500 000 IU cholecalciferol versus placebo in women aged over 70 years (83.4 per 100 person-years vs. 72.7, respectively, P = 0.03). It should be noted, however, that only 3% of sub-study participants who had serum 25OHD assessed had concentrations under 25 nmol/l, and these findings may not be generalizable to cohorts with a higher prevalence of vitamin D deficiency. 15 Monitoring of calcium levels was advised to avoid hypercalcaemia secondary to 'unmasking' of primary hyperparathyroidism. Toxicity is thought unlikely in doses under 10 000 IU/day, with the European Food Safety Authority (EFSA) advising doses under 4000 IU/day. Problems in interpreting the results of RCTs include small sample sizes, heterogeneity in type, dose and route of administration, populations and baseline, and follow-up vitamin D status in many studies.
Laboratory analyses
It is important to recognize that 25OHD is a relatively inactive metabolite, so that its actions on target tissues are dependent on either systemic or localized metabolism to other vitamin D metabolites. The use of serum 25OHD concentration as the primary marker of 'vitamin D status' has obvious advantages in terms of longer half-life and serum stability. In addition, there is a direct link between vitamin D supplementation/restriction and serum concentrations of 25OHD. In contrast, serum concentrations of calcitriol are dependent not only on 25OHD, but also PTH, and FGF23 that coordinate renal expression of 1α-hydroxylase. 13 In addition, there is debate as to whether unbound/bioavailable 25OHD may be a more physiologically meaningful measure of overall status, the hypothesis being that this is the fraction that is available for 1α-hydroxylation and extraskeletal action. There is also controversy as to the significance of previously reported racial differences in DBP levels. One particular study reported that circulating DBP levels were lower in African-Americans, so that bioavailable 25OHD levels were similar to other racial groups despite lower measured total levels in African-Americans. 16 However, recent reports suggest that these data are confounded by the use of a monoclonal rather than a polyclonal ELISA accounting for the racial differences in DBP. 17 In addition, high-throughput methods of multi-metabolite vitamin D analysis using liquid chromatography-mass spectrometry have been developed, which will enable more thorough assessment of vitamin D status. 18 Well-designed large-scale supplementation studies are required to resolve the areas of controversy surrounding dosing strategies. In particular in determining appropriate target thresholds of vitamin D for skeletal health and other indications, along with optimum dosing regimens. In addition, further work is required on determining the physiological importance of different vitamin D metabolites and the impact of protein binding. 
Seasonal variability in serum 25OHD concentrations
Growing points
Researchers have investigated the extra-skeletal roles of vitamin D using a range of approaches from in vitro and in vivo animal studies through to human observational studies and interventional trials. 22 The central themes and controversies that stem from this work, concern questions regarding:
(1) Whether vitamin D deficiency has a causative role in disease associations from observational studies; this includes whether potential confounders have been controlled for (including sunlight exposure, diet and activity) (2) Whether vitamin D supplementation trials have been well designed (particular issues include lack of statistical power, limited follow up and reporting of pre-post-intervention serum levels, and adverse events).
Our current understanding of the effect of vitamin D in a range of extra-skeletal disease areas is briefly outlined as follows.
Muscle function
There is evidence that vitamin D may regulate calcium flux in muscle at the cellular level, in addition to its established role in whole body calcium balance. 23, 24 It is thus theorized that it exerts direct calcium-dependent effects on muscle contraction, as well as independent effects. In addition, vitamin D is thought to have genomic effects (i.e. those that result in a change in gene transcription) via binding to the VDR-RXR heterodimer, and non-genomic effects on signal transduction pathways. There is some controversy as to the level of expression of VDR in adult human muscle, whereby some authors have questioned the validity of the antibodies used for expression analyses in earlier studies. 25 A range of studies have confirmed VDR expression in animal tissues and cell culture models. In vitro work suggests that calcitriol regulates muscle cell differentiation and proliferation via effects on MAPK signalling pathways. There is also evidence of effects on expression of muscle cytoskeletal proteins, changes in phospholipid composition and on glucose transport. Mice with global deletion of VDR (VDRKO) have muscle atrophy from an early stage, with progression that is not attenuated by a diet high in calcium and phosphorus. 25 Subsequent studies have confirmed that overall motor function is impaired in VDRKO mice.
26
A number of single-nucleotide polymorphisms in the human VDR gene have been described, which are associated with changes in measures of muscle strength and function. 25 More recently a metaanalysis of 26 randomized controlled trials and with 45 782 participants found that vitamin D use with calcium was associated with a reduced risk of falls (OR 0.86, 95% CI 0.77-0.96), with the effect being stronger in those who had lower levels at baseline. 27 Authors of another meta-analysis of 30
RCTs (n = 5615 participants) reported a small significant effect on global muscle strength, with the effects being more marked in those with a serum 25OHD concentration <30 nmol/l. 28 These increases in strength were especially observed in the lower limbs. No effect was observed on the muscle mass or muscle power, where studies were reported to be of low quality. Subgroup analyses revealed that vitamin supplementation resulted in improvements in muscle strength in those over 65 years, whereas no effect was seen in younger groups. The effects were also stronger in institutionalized rather than community dwelling cohorts. 28 to block production of pro-inflammatory cytokines via inhibition of p38 MAP kinase and NF-κB signalling. 33 Studies of transgenic mice with deletions of genes involved with vitamin D signalling and metabolism suggest that its role in adipose tissue regulation is more complex, however, with VDRKO mice having reduced bodyweights and resistance to obesity on high-fat diet, and adipose tissue-specific VDRKO increasing bodyweight and adipose tissue depots. 34 Observational studies in humans have confirmed an inverse relationship between serum 25OHD and fat mass, with a high prevalence of vitamin D deficiency in obesity such that weight loss is associated with increasing levels. 35 Volumetric dilution or sequestration of vitamin D in adipose tissue have been proposed as explanations for this effect and there is no evidence that vitamin D has an anti-obesity effect in humans. 35 A number of studies have linked vitamin D status to insulin resistance and diabetes risk. Whilst no improvement in HbA1c or markers of glycaemic control and insulin resistance were seen with vitamin D supplementation across the group as a whole in a recent systemic review, small effects on fasting glucose and insulin resistance were seen in patients with diabetes and impaired glucose tolerance. 36 A recent study also concluded that 5 years supplementation of vitamin D 20 000 IU/week in 511 participants with pre-diabetes failed to prevent progression to diabetes. 37 There has been recent focus on the relationship with non-alcoholic fatty liver disease (NAFLD) with a meta-analysis of 17 studies (4855 cases and 7939 controls), confirming that NAFLD patients have lower 25OHD levels (difference in serum 25OHD concentration between cases and controls = 0.36 ng/ml 95% CI 0.32-0.40). It should be noted, however, that although statistically significant, the magnitude of differences in serum 25OHD concentrations is likely to be of negligible clinical significance. Previous work suggested that effects of vitamin D on liver fibrosis, apoptosis and inflammation were putative underpinning mechanisms of the association. 38 Evidence suggests that vitamin D has beneficial effects on vascular and endothelial function via modulation of inflammatory cytokines, nitric oxide, the renin-angiotensin-aldosterone system and mediators of thrombus formation. 39 Inverse relationships between serum vitamin D and risk factors for cardiovascular disease, including blood pressure and coronary calcification, have been reported in observational studies in addition to those outlined above. A meta-analysis that included data from 51 supplementation studies did not demonstrate any benefit on myocardial infarction, stroke, serum lipids or blood pressure. 40 In addition, there have been widely reported concerns from the analysis of the Women's Health Initiative Study on excess cardiovascular disease risk associated with calcium supplementation. 41 Neurological disease Vitamin D deficiency was identified as a potential risk factor in MS in the early 1970s following the clear observation of increasing incidence with latitude. 42 Month of birth also appears to be associated with differential risk of developing MS, with those born in April having a significant excess risk, and those born in October and November having a risk reduction. 21 This review only included cases from the northern hemisphere, and it is likely that the findings will be different in the south. Observational studies have also confirmed an inverse association between serum vitamin D levels and MS risk. 42 A meta-analysis did not demonstrate any benefit of high dose vitamin D on incidence of MS relapse in patients; 43 however, the number of participants included was small (n = 129 cases vs. 125 controls). Large-scale supplementation studies are required to address the question of the influence of vitamin D in MS risk and disease activity.
There is interest in the potential neuroprotective effects of vitamin D, particularly with regard to dementia prevention. Proposed mechanistic effects of vitamin D on the central nervous system include those calcium metabolism, inflammation, cell stress and on specific neurodegenerative processes. 44 Once again, observational studies reported associations between vitamin D status and cognitive performance (including executive function, processing speed and working memory) as well as incidence of dementia. Randomized trial evidence is limited, however, with relatively small numbers of participants to date. 44 
Infection and immunity
Vitamin D has modulatory roles in the innate and adaptive immune systems, which are required in the response to respiratory pathogens including TB. 45 In vitro studies showed vitamin D had antituberculous activity in the 1980s. 46 More recent work has demonstrated that 1,25(OH) 2 D acts directly to increase expression of a number of antimicrobial peptides including cathelicidin. 47 In the adaptive immune system, vitamin D stimulates development of suppressive regulatory T cells and suppressed development of pro-inflammatory Th17 cells. 45 A 2008 systematic review and meta-analysis of observational studies, published between 1980 and 2006 showed that serum 25OHD concentrations were lower in TB cases, compared to healthy controls. 48 A 'medium to large effect' was observed and there was reported to be little heterogeneity in the results of the studies. A large New York-based study (n = 34 004) showed that 21.9% of TB cases were diagnosed in autumn (September to November) compared to 27.3% in spring (March to May). 20 The authors acknowledged vitamin D status as being a potential cause of this phenomenon; however, 'winter crowding' was listed as another possibility. The seasonal variation in TB incidence has been observed globally. [49] [50] [51] Observational studies have also demonstrated significant associations between vitamin D status and incidence of TB in contacts 52 and in activation of latent TB. 53 When this area was recently reviewed by the SACN; however, no RCTs examining the role of vitamin D supplementation in TB were found. 2 With regard to respiratory tract infections more broadly, a recent meta-analysis found insufficient evidence to demonstrate a protective effect of vitamin D supplementation. 54 Fifteen trials with 7053 participants were included, heterogeneity in outcome was large and overall study quality was low. The findings were in agreement with the previous meta-analysis by Mao and Huang, 55 but were contrary to those from two other groups. 56, 57 There was discussion as to whether 63 Previous meta-analyses demonstrated excess mortality of a similar magnitude, and that mortality (all-cause RR = 0.89, 95% CI 0.80-0.99) was reduced in patients taking vitamin D3 as part of RCT protocols. 64 Cancer mortality was only increased in those with a past history of malignancy. 63 The clinical findings were consistent across regions, time of year and according to sex and age. The study authors suggested that region and population specific vitamin D thresholds should be established for use in clinical practice. A large Danish study (n = 95 766) took a mendelian randomization approach in an attempt to remove the influence of potential confounders. 65 Participants were genotyped for variants in genes (DHCR7/CYP2R1) known to affect circulating 25OHD levels. The findings indicated that genetically determined vitamin D levels were associated with changes in cancer and all-cause mortality, but not CVD mortality. The Cochrane review team concluded, however, that there is insufficient evidence at present to confirm whether vitamin D supplementation is associated with reduced mortality. 66 This review took into account data from 56 RCTs (n = 95 286) with usable data on mortality from developed countries. The results suggested that mortality is reduced in elderly ambulatory individuals, who would be at risk of falls, however, when potential confounders were controlled for the findings did not reach statistical significance.
Areas timely for developing research
Well-designed clinical studies of the extra-skeletal effects of vitamin D are much needed. Particular limitations at present include the lack of well-powered studies in this area; data on pre-/post-intervention vitamin D status, recording of adverse events and comparison of different dosing regimens. It is notable that the vast majority of studies have been carried out in the USA and Europe, it is imperative that studies are carried out with a diverse range of participants (age, gender, ethnicity), and settings for the findings to be generalizable to the wider population. In addition, we would advocate the use of research tools in human studies to advance our understanding of the mechanisms of vitamin D action in extraskeletal disease. This may involve multi-metabolite analysis or unbiased approaches to assess regulation of gene/protein expression in tissues of interest.
There are a number of large-scale (>10 000 participants), randomized, placebo controlled trials of vitamin D for extra-skeletal outcomes (including cardiovascular disease, cancer and overall mortality) expected to report by the end of the decade. Examples listed on clinicaltrials.gov include the Vitamin D and Omega-3 trial, which is estimated to complete in December 2017, and the Finnish Vitamin D trial, estimated to complete in December 2018. These studies will represent a leap forward in our understanding of this area and will provide clarity for clinical guidelines and future practice.
Conclusions
Vitamin D deficiency is prevalent worldwide, and its causal role in rickets and osteomalacia remains an important public health problem. The importance of vitamin D for musculoskeletal health is also wellestablished, although further research is required to optimize treatment regimens and target serum thresholds. Pre-clinical and observational research is linked with a number of diseases; however, large-scale RCTs are required to confirm whether these observations are of clinical significance.
